Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Azenta, Inc. - Common Stock (NQ:AZTA)

27.16 -0.22 (-0.80%)
Streaming Delayed Price Updated: 1:49 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Azenta Inc (NASDAQ:AZTA) Reports Q4 2025 Earnings Beat and Positive Market Reaction ↗
Azenta (AZTA) reports Q4 FY2025 results, beating EPS estimates with $0.21 and slightly missing on revenue. The stock rose on the positive earnings news. 
Via Chartmill
Topics Earnings
News headline image
Azenta (NASDAQ:AZTA) Surprises With Q3 CY2025 Sales
Life sciences company Azenta (NASDAQ:AZTA) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.5% year on year to $159.2 million. Its non-GAAP profit of $0.19 per... 
Via StockStory
News headline image
Earnings Outlook For Azenta ↗
 
Via Benzinga
News headline image
Azenta (AZTA) Reports Q3: Everything You Need To Know Ahead Of Earnings
Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Friday before the bell. Here’s what to look for. 
Via StockStory
News headline image
3 Unprofitable Stocks We’re Skeptical Of
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
1 Cash-Producing Stock to Consider Right Now and 2 We Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
1 Stock Under $50 for Long-Term Investors and 2 We Turn Down
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
1 High-Flying Stock with Promising Prospects and 2 That Underwhelm
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
News headline image
3 Russell 2000 Stocks We Think Twice About
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
This Coinbase Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the... 
Via StockStory
Topics Economy Stocks
News headline image
LifeStance Health Group, Azenta, PacBio, GE HealthCare, and ICU Medical Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
3 Stocks Under $50 We’re Skeptical Of
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Topics Supply Chain
News headline image
Spotting Winners: Azenta (NASDAQ:AZTA) And Drug Development Inputs & Services Stocks In Q2
Let’s dig into the relative performance of Azenta (NASDAQ:AZTA) and its peers as we unravel the now-completed Q2 drug development inputs & services earnings season. 
Via StockStory
News headline image
Repligen, Revvity, Avantor, Fortrea, and Azenta Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics Economy
News headline image
3 Unprofitable Stocks We Steer Clear Of
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
News headline image
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Earnings Economy
News headline image
AZTA Q2 Deep Dive: Product Mix Shifts and Cost Controls Define Flat Quarter
Life sciences company Azenta (NASDAQ:AZTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $143.9 million. Its non-GAAP profit of $0.14 per share was in... 
Via StockStory
Topics Economy
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Stocks
News headline image
1 Cash-Producing Stock to Consider Right Now and 2 Facing Headwinds
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
1 Small-Cap Stock to Research Further and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
Why Azenta (AZTA) Stock Is Up Today
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 3.3% in the afternoon session after an upgrade from investment firm Raymond James, which lifted its rating to 'outperform' from 'market... 
Via StockStory
Topics Artificial Intelligence
News headline image
Azenta (AZTA) Stock Trades Up, Here Is Why
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 5% in the afternoon session after Raymond James upgraded the stock to 'Outperform' from 'Market Perform' and set a $35 price target. The... 
Via StockStory
News headline image
Azenta (AZTA) Q3 EPS Jumps 36% ↗
Via The Motley Fool
News headline image
Why Azenta (AZTA) Stock Is Trading Lower Today
Shares of life sciences company Azenta (NASDAQ:AZTA) fell 16.3% in the afternoon session after the company announced mixed third-quarter financial results, where a failure to meet revenue targets... 
Via StockStory
Topics Artificial Intelligence Stocks World Trade
News headline image
Azenta Inc (NASDAQ:AZTA) Reports Mixed Q3 2025 Earnings: Revenue Miss but EPS Beat ↗
Azenta Inc (AZTA) reported mixed Q3 FY2025 results, missing revenue estimates but beating EPS. The company maintained full-year guidance amid investor caution. 
Via Chartmill
News headline image
Azenta (NASDAQ:AZTA) Misses Q2 Sales Targets
Life sciences company Azenta (NASDAQ:AZTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $143.9 million. Its non-GAAP profit of $0.14 per share was in... 
Via StockStory
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.